1 |
Lanvers-Kaminsky C. Asparaginase pharmacology: challenges still to be faced. Cancer Chemother Pharmacol 2017;79(3):439-450.
DOI
|
2 |
Land VJ, Sutow WW, Fernbach DJ, et al. Toxicity of L-asparginase in children with advanced leukemia. Cancer 1972;30(2):339-47.
DOI
|
3 |
Raetz E, Salzer W. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2010;32(7):554-63.
DOI
|
4 |
Hijiya N, van der Sluis IM. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma 2016;57(4):748-57.
DOI
|
5 |
Marquet K, Claes N, De Troy E, et al. A multicenter record review of in-hospital adverse drug events requiring a higher level of care. Acta Clin Belg 2017;72(3):156-62.
DOI
|
6 |
Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ (Clinical research ed) 2004;329 (7456):15-9.
DOI
|
7 |
Ladewski LA, Belknap SM, Nebeker JR, et al. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol 2003;21(20):3859-66.
DOI
|
8 |
Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999;281(9):824-9.
DOI
|
9 |
Jong-Mi Seong, Byung-Joo Park. Recent advance in pharmacovigilance activities of World Health Organization and U.S Food and Drug Administration. Korean Public Health Research 2015;41(2):19-28.
|
10 |
Bushman JE, Palmieri D, Whinna HC, et al. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res 2000;24(7):559-65.
DOI
|
11 |
Medical Dictionary for Regulatory Activities. International Conference on Harmonization. Available from https://www.meddra.org/browsers. Accessed Oct. 1, 2016.
|
12 |
WHO-Uppsala Monitoring Center causality category. World Health Organization. Available from https://www.who-umc.org. Accessed Jan. 1, 2014.
|
13 |
Common Terminology Criteria for Adverse Events version 4.0. National Health Institute. Available from https://evs.nci.nih.gov/ftp1/CTCAE. Accessed Oct. 1, 2016.
|
14 |
Buchanan GR, Holtkamp CA. Reduced antithrombin III levels during L-asparaginase therapy. Med Pediatr Oncol 1980;8(1):7-14.
DOI
|
15 |
Merlen C, Bonnefoy A, Wagner E, et al. L-Asparaginase lowers plasma antithrombin and mannan-binding-lectin levels: Impact on thrombotic and infectious events in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2015;62(8):1381-7.
DOI
|
16 |
Hunault Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica 2008;93(10):1488-94.
DOI
|
17 |
Ranta S, Heyman M, Jahnukainen K, et al. Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis. 2013;24(7):749-56.
DOI
|
18 |
Stock W, Douer D, DeAngelo D, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma 2011;52(12):2237-53.
DOI
|
19 |
Bodmer M, Sulz M, Stadlmann S, et al. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with Lasparaginase. Digestion 2006;74(1): 28-32.
DOI
|
20 |
Sahoo S, Hart J. Histopathological features of L-asparaginase-induced liver disease. Semin Liver Dis 2003;23(3):295-9.
DOI
|
21 |
Durden DL, Salazar AM, Distasio JA. Kinetic analysis of hepatotoxicity associated with antineoplastic asparaginases. Cancer Res 1983;43(4):1602-5.
|
22 |
Murakawa M, Okamura T, Shibuya T, et al. Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation. Ann Hematol 1992;64(5):249-52.
DOI
|
23 |
Cohen H, Bielorai B, Harats D, et al. Conservative treatment of Lasparaginase- associated lipid abnormalities in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;54(5):703-6.
DOI
|
24 |
Nesheli HM, Tamaddoni A, Nesheli MM, et al. L-asparaginase induced hyperlipidaemia in acute lymphoblastic leukaemia. J Pak Med Assoc 2013;63(3):324-6.
|
25 |
Bhojwani D, Darbandi R, Pei D, et al. Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia. Eur J Cancer 2014;50(15):2685-94.
DOI
|
26 |
Wang B, Relling MV, Storm MC, et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003;17(8):1583-8.
DOI
|
27 |
Whitecar JP, Bodey GP, Harris JE, et al. L-asparaginase. The New Eng J Med 1970;282(13):732-4.
DOI
|
28 |
Clarkson B, Krakoff I, Burchenal J, et al. Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors. Cancer 1970;25(2): 279-305.
DOI
|